We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00589186
Recruitment Status : Unknown
Verified December 2008 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : January 9, 2008
Last Update Posted : December 18, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Vaccines made from a gene-modified virus and a person's dendritic cells may help the body build an effective immune response to kill tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with celecoxib may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving vaccine therapy together with celecoxib works in treating patients with metastatic nasopharyngeal cancer.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Biological: Ad5F35-LMP1/LMP2-transduced autologous dendritic cells Drug: celecoxib Other: flow cytometry Other: immunoenzyme technique Other: laboratory biomarker analysis Phase 2

Detailed Description:



  • To evaluate the clinical benefit rate (complete response, partial response, and stable disease for ≥ 14 weeks) in patients with metastatic nasopharyngeal carcinoma treated with autologous dendritic cells (DC) transduced with AD5F35 expressing LMP-1 and LMP-2 when administered in combination with celecoxib.


  • To evaluate the toxicities of this regimen in these patients.
  • To evaluate the specific T-cell response against LMP-1 and LMP-2 as measured by HLA tetramer technology, ELISPOT assay, and delayed-type hypersensitivity in patients treated with this regimen.
  • To evaluate the surrogate tumor marker response plasma EBV DNA by real-time PCR in these patients.
  • To evaluate and characterize immunological cell types and tumor characteristics in biopsy specimens of patients treated with this DC vaccine and compare it with pre-vaccine biopsy specimens.
  • To evaluate progression-free survival and overall survival of patients who show initial clinical benefit to DC vaccine.

OUTLINE: Patients undergo blood collection for the preparation of the autologous dendritic cell (DC) vaccine. Immature DCs are transduced with latent membrane protein-1 (LMP-1) and latent membrane protein-2 (LMP-2) using the adenoviral vector 5F35. Beginning 1 week after blood collection, patients receive vaccination with autologous DCs transduced with AD5F35-LMP-1/LMP-2 intradermally every 2 weeks for a total of 5 vaccinations. Patients also receive celecoxib twice a day beginning 1 week before the first vaccination and continuing for up to 6 weeks after completion of the last vaccination.

Patients who demonstrate clinical benefit after completion of 5 courses of vaccination may continue to receive the DC vaccine alone off study every 2 weeks until disease progression (based on CT scan findings) or at the investigator's discretion.

Patients undergo blood and tumor tissue sample collection periodically for laboratory studies. Blood samples are analyzed using MHC tetramer analysis; enzyme-linked immunospot (ELISPOT) analysis; EBV DNA titers to assess response; and flow cytometry to assess lymphocyte kinetics. Tumor tissue samples are used for immunological studies. Delayed-type hypersensitivity is also assessed.

After completion of study treatment, patients are followed monthly for up to 1 year.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Clinical Trial of Tumour Vaccination By Intradermal Delivery of Autologous Dendritic Cells Transduced With Adenoviral Vector (AD5F35) Expressing Latent Membrane Protein-1 (LMP-1) and Latent Membrane Protein-2 (LMP-2) Genes in Combination With Celecoxib in Patient With Metastatic Nasopharyngeal Carcinoma
Study Start Date : November 2007
Estimated Primary Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vaccines
Drug Information available for: Celecoxib

Primary Outcome Measures :
  1. Clinical benefit rate (CBR) (complete response [CR], partial response [PR], and stable disease [SD] for ≥ 14 weeks) as defined by RECIST criteria

Secondary Outcome Measures :
  1. Response rate (CR and PR)
  2. Overall survival
  3. Progression-free survival
  4. Toxicity profile

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed nasopharyngeal carcinoma (NPC)

    • Metastatic disease
    • WHO type II/III disease
  • Measurable disease
  • Meets 1 of the following criteria:

    • Progression on one or more lines of polychemotherapy for treatment of metastatic disease
    • Failed non-myeloablative hematopoietic stem cell transplant
  • No active CNS metastases


  • ECOG performance status 0-2
  • Life expectancy > 3 months
  • Hemoglobin ≥ 8.5 g/dL
  • Serum bilirubin ≤ 1.5 times upper limit of normal
  • ALT or AST ≤ 5 times normal
  • Creatinine clearance ≥ 40 mL/min
  • Left ventricular ejection fraction ≥ 45% by MUGA
  • Corrected DLCO > 50% of predicted
  • No active or prior gastrointestinal bleeding
  • No history of adverse reaction to NSAIDs or sensitivity to celecoxib
  • No cardiac disease, including any of the following:

    • Symptomatic congestive heart failure
    • Active angina pectoris
    • High-risk uncontrolled arrhythmia
    • Uncontrolled hypertension
  • No pulmonary disease, including any of the following:

    • Severe chronic obstructive lung disease
    • Uncontrolled large pleural effusion
    • Severe restrictive lung disease
  • No cerebrovascular accident
  • No transient ischemic attack
  • No HIV positivity
  • No active uncontrolled infection
  • No symptomatic leukoencephalopathy or other neuropsychiatric abnormalities
  • Not pregnant or nursing
  • Negative pregnancy test


  • See Disease Characteristics
  • Prior celecoxib allowed
  • At least 28 days since prior chemotherapy
  • At least 100 days since prior non-myeloablative hematopoietic stem cell transplant
  • At least 2 months since prior donor lymphocyte infusions
  • More than 28 days since prior participation in another clinical trial with any investigational drugs
  • No other concurrent experimental drugs
  • No other concurrent anticancer therapy
  • No concurrent anticoagulation with warfarin or low molecular weight heparin
  • No other concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00589186

Layout table for location information
National Cancer Centre - Singapore
Singapore, Singapore, 169610
Sponsors and Collaborators
National Cancer Centre, Singapore
Layout table for investigator information
Study Chair: Toh Han Chong, MD, MBBS, MRCP National Cancer Centre, Singapore
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00589186    
Other Study ID Numbers: CDR0000579355
First Posted: January 9, 2008    Key Record Dates
Last Update Posted: December 18, 2013
Last Verified: December 2008
Keywords provided by National Cancer Institute (NCI):
stage IV squamous cell carcinoma of the nasopharynx
stage IV lymphoepithelioma of the nasopharynx
recurrent squamous cell carcinoma of the nasopharynx
recurrent lymphoepithelioma of the nasopharynx
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action